Mesoblast Readies for Ryoncil® Rollout and Expands Its Late-Stage Pipeline

Mesoblast (Nasdaq: MESO; ASX: MSB) is moving forward with the U.S. commercial launch of Ryoncil® (remestemcel-L), the first and only FDA-approved mesenchymal stromal cell (MSC) therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). With final preparations underway, including logistics, regulatory documentation, and distribution infrastructure, the company remains on track for a full rollout.

Backed by a $160 million financing, Mesoblast is well-positioned to execute its launch strategy, expand indications for Ryoncil®, and advance its late-stage pipeline. The company’s lead assets, Revascor® for heart failure and Rexlemestrocel-L for chronic low back pain, each targeting multi-billion-dollar markets, are progressing toward key regulatory milestones.

As of December 31, 2024, the company reported $38 million cash on hand.